$OBIO

Sherman Darren sold $61K of OBIO

Sherman Darren (See Remarks) sold 15,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.09 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sherman Darren
Published Aug 4, 2026, 8:49 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OBIO
Neutral
high confidence
Mentioned
$OBIO
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OBIONeutralLow
01

Why it matters

The newest disclosed fact is the specific insider sale size, price, and post-transaction holdings, but it does not include any new company performance or guidance information.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure and lack of fundamental updates make it low signal.

03

What to watch

The article does not state whether this sale is part of a larger series, whether other insiders sold/bought, or whether there were concurrent company-specific catalysts.

Relevance 2/10Novelty 3/10Timing: filed Aug 4 after-hours; transaction dated Aug 3

Background

The article is a SEC Form 4 insider transaction filing for Orchestra BioMed Holdings, Inc. (OBIO).

Company-level read

Ticker impact

$OBIONeutralHigh confidence
Context

Orchestra BioMed Holdings disclosed a Form 4 insider open-market sale of 15,000 shares at $4.09 on Aug 3 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted unless accompanied by other news.

Evidence & confidence

The filing is an insider transaction with a pre-arranged 10b5-1 plan, and the article provides no new operational, financial, or regulatory catalyst.

Market effects

No clear sector read-through from a single routine 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still reflect management’s risk management or valuation views, which some traders may front-run.

Key entities

  • Orchestra BioMed Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Sherman Darren

    Officer and director who sold 15,000 shares in an open-market transaction under a 10b5-1 plan.

Related articles